Skip to main content
IceCure Medical Ltd. logo

IceCure Medical Ltd. — Investor Relations & Filings

Ticker · ICCM ISIN · IL0011224156 US Manufacturing
Open in API
Filings indexed 261 across all filing types
Latest filing 2026-06-02 Share Issue/Capital Cha…
Country US United States of America
Listing US ICCM

About IceCure Medical Ltd.

https://icecure-medical.com/

IceCure Medical Ltd. is a medical device company that develops and markets advanced cryoablation systems for the minimally invasive treatment of benign and malignant tumors. The company's core technology utilizes liquid nitrogen to achieve ultra-cold temperatures, enabling the precise freezing and destruction of targeted tissue while leaving adjacent tissue unharmed. Its flagship product, the ProSense® Cryoablation System, is used as an alternative to surgical tumor removal in various applications, including for the treatment of low-risk, early-stage breast cancer. The procedure is designed to be quick, performed under local anesthesia with a short recovery time. The company also develops systems for use in fields such as general surgery, dermatology, and neurology.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Share Issue/Capital Change Classification · 90% confidence The document is a Form 6-K (Report of Foreign Private Issuer) furnishing a press release titled “IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance.” This is an announcement of a corporate action changing the capital structure (reverse share split). It does not contain full financial statements, earnings data, or management discussion – it merely announces a capital change. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-06-02 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 90% confidence The document is a Form 6-K, which is a current report of a foreign private issuer filed with the SEC to furnish a press release (Exhibit 99.1). It does not contain substantive financial statements or detailed analysis, nor is it a proxy, dividend, or earnings release per se. It is a regulatory filing for compliance purposes, making “Regulatory Filings (RNS)” the appropriate category.
2026-05-19 English
6-K - IceCure Medical Ltd. (0001584371) (Filer)
Regulatory Filings Classification · 85% confidence The document is a Form 6-K (Report of Foreign Private Issuer) submitted under the Exchange Act, furnishing a press release as Exhibit 99.1 regarding Nasdaq compliance. It does not contain financial statements itself, nor is it an annual or interim report; it is a regulatory disclosure filing. This falls under general regulatory announcements and does not fit other specific categories.
2026-05-13 English
424B5 - IceCure Medical Ltd. (0001584371) (Filer)
Capital/Financing Update Classification · 90% confidence The document is a prospectus supplement filed on Form 424(b)(5) relating to an at-the-market equity offering of up to $4.34 million of ordinary shares under a shelf registration. It details the sales agreement with A.G.P. for the sale of new shares, outlining the offering terms, plan of distribution, use of proceeds, and related financing arrangements. This clearly constitutes a capital raising/financing update rather than a report of financial results, management changes, or other categories.
2026-05-12 English
6-K - IceCure Medical Ltd. (0001584371) (Filer)
Regulatory Filings Classification · 82% confidence The document is a Form 6-K “Report of Foreign Private Issuer” filed under the Securities Exchange Act, furnishing a press release as Exhibit 99.1. It does not itself contain full financial statements or constitute an Annual or Interim Report, nor is it a standalone earnings release or investor presentation. It is a SEC regulatory filing for a foreign private issuer and thus falls under the general Regulatory Filings category.
2026-05-12 English
6-K - IceCure Medical Ltd. (0001584371) (Filer)
Declaration of Voting Results & Voting Rights Announcements Classification · 87% confidence The document is a Form 6-K “Report of Foreign Private Issuer” that discloses the convening, adjournment, reconvening, and ultimate shareholder vote approval at a Special General Meeting. It specifically reports the voting results on the agenda item. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-11 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.